Sage Therapeutics Inc Net Assets
Sage Therapeutics Inc net assets. Based on the latest financial reports, Sage Therapeutics Inc (SAGE) has net assets worth $368.74 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($422.92 Million) and total liabilities ($54.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Sage Therapeutics Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $368.74 Million |
| % of Total Assets | 87.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | -77.56% |
| 10-Year Change | 167.76% |
| Growth Volatility | 57.37 |
Net Assets of Sage Therapeutics Inc (2012–2024)
Net assets of Sage Therapeutics Inc from 2012 to 2024. This chart illustrates how Sage Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Sage Therapeutics Inc (SAGE) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Sage Therapeutics Inc (2012–2024)
The table below shows the annual net assets of Sage Therapeutics Inc from 2012 to 2024. For live market cap and overall valuation, see SAGE market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $465.09 Million | -41.83% |
| 2023-12-31 | $799.53 Million | -36.17% |
| 2022-12-31 | $1.25 Billion | -27.55% |
| 2021-12-31 | $1.73 Billion | -16.57% |
| 2020-12-31 | $2.07 Billion | +119.37% |
| 2019-12-31 | $944.65 Million | +9.47% |
| 2018-12-31 | $862.97 Million | +81.50% |
| 2017-12-31 | $475.48 Million | +29.02% |
| 2016-12-31 | $368.52 Million | +112.16% |
| 2015-12-31 | $173.69 Million | +42.51% |
| 2014-12-31 | $121.89 Million | +486.49% |
| 2013-12-31 | $-31.54 Million | -135.45% |
| 2012-12-31 | $-13.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sage Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 295693100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Sage Therapeutics Inc Net Assets Breakdown (December 2024)
Sage Therapeutics Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $244.00K | 0.05% |
| Other Components | $3.44 Billion | 738.60% |
| Total Equity | $465.09 Million | 100.00% |
Sage Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Sage Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prism Johnson Limited
NSE:PRSMJOHNSN
|
$544.96 Million |
|
Northrim BanCorp Inc
NASDAQ:NRIM
|
$545.00 Million |
|
KINX Inc
KQ:093320
|
$545.06 Million |
|
Shenzhen Refond Optoelectronics Co Ltd
SHE:300241
|
$545.14 Million |
|
HANA Micron Inc
KQ:067310
|
$544.85 Million |
|
Changzhou Almaden Co Ltd
SHE:002623
|
$544.68 Million |
|
Continental Holdings Corp
TW:3703
|
$544.65 Million |
|
Guangdong Mingzhu Group Co Ltd
SHG:600382
|
$544.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sage Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 799,530,000 to 465,089,000, a change of -334,441,000 (-41.8%).
- Net loss of 400,666,000 reduced equity.
- New share issuances of 8,164,000 increased equity.
- Other comprehensive income increased equity by 1,058,000.
- Other factors increased equity by 57,003,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-400.67 Million | -86.15% |
| Share Issuances | $8.16 Million | +1.76% |
| Other Comprehensive Income | $1.06 Million | +0.23% |
| Other Changes | $57.00 Million | +12.26% |
| Total Change | $- | -41.83% |
Book Value vs Market Value Analysis
This analysis compares Sage Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.54 | $8.68 | x |
| 2013-12-31 | $-1.26 | $8.68 | x |
| 2014-12-31 | $5.65 | $8.68 | x |
| 2015-12-31 | $6.25 | $8.68 | x |
| 2016-12-31 | $11.00 | $8.68 | x |
| 2017-12-31 | $12.48 | $8.68 | x |
| 2018-12-31 | $18.71 | $8.68 | x |
| 2019-12-31 | $18.58 | $8.68 | x |
| 2020-12-31 | $39.10 | $8.68 | x |
| 2021-12-31 | $29.47 | $8.68 | x |
| 2022-12-31 | $21.12 | $8.68 | x |
| 2023-12-31 | $13.36 | $8.68 | x |
| 2024-12-31 | $7.65 | $8.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sage Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -86.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -971.48%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.18x
- Recent ROE (-86.15%) is below the historical average (-37.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.29 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.13 Million |
| 2014 | -27.74% | 0.00% | 0.00x | 1.06x | $-46.00 Million |
| 2015 | -54.40% | 0.00% | 0.00x | 1.09x | $-111.86 Million |
| 2016 | -43.14% | 0.00% | 0.00x | 1.10x | $-195.84 Million |
| 2017 | -56.81% | 0.00% | 0.00x | 1.11x | $-317.67 Million |
| 2018 | -43.21% | -413.06% | 0.09x | 1.10x | $-459.18 Million |
| 2019 | -68.82% | -9466.38% | 0.01x | 1.15x | $-744.62 Million |
| 2020 | 29.25% | 54.40% | 0.52x | 1.04x | $398.84 Million |
| 2021 | -26.07% | -7146.91% | 0.00x | 1.06x | $-623.73 Million |
| 2022 | -40.18% | -6547.84% | 0.01x | 1.08x | $-628.53 Million |
| 2023 | -67.73% | -626.32% | 0.10x | 1.10x | $-621.44 Million |
| 2024 | -86.15% | -971.48% | 0.08x | 1.18x | $-447.17 Million |
Industry Comparison
This section compares Sage Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sage Therapeutics Inc (SAGE) | $368.74 Million | 0.00% | 0.15x | $544.94 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more